Loading...
Market
Which treatment will have the largest market share for r/r B-ALL in US by end of 2025?
2
Resolution / Starting Odds
Aucatzyl (Autolus Therapeutics) • 25%
Kymriah (Novartis) • 25%
Yescarta (Gilead) • 25%
Other • 25%
Market share reports from healthcare market analysis firms
Story
FDA Approves Autolus Therapeutics' Aucatzyl for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Under FELIX Program
Nov 8, 2024, 09:24 PM
The U.S. Food and Drug Administration (FDA) has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel – obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This approval, part of the FELIX program, marks a significant milestone for the company and provides a new treatment option for patients suffering from this aggressive form of leukemia. Despite earlier rumors and a temporary dip in share prices, the official announcement has confirmed the FDA's decision, which is expected to positively impact Autolus Therapeutics' market position.
View original story
Similar markets
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Apitegromab • 25%
Evrysdi • 25%
Spinraza • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Kisunla™ > Leqembi • 25%
Leqembi > Kisunla™ • 25%
Kisunla™ and Leqembi have equal market share • 25%
Other treatments lead • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%